title: Polymorphisms in the genes related to angiogenesis are associated with uterine cervical cancer.
abstract: BACKGROUND
  The expression of plasminogen activator inhibitor type 1 (PAI-1), vascular endothelial growth factor (VEGF), and transforming growth factor β1 (TGF-β1) participates in the angiogenesis of several cancer types. The goal of this study was to investigate polymorphisms in genes related to angiogenesis (PAI-1-675 4G/5G, VEGF C936T, and TGF-β1 G-800A) to evaluate the risk for developing uterine cervical cancer (UCC).
  
  
  METHODS
  In a case-control study, 100 healthy subjects and 100 patients with UCC from Mexico were included. We determined the genetic profile of the polymorphic markers, which were evaluated by polymerase chain reaction using a sequence-specific primer.
  
  
  RESULTS
  There was no statistical difference in the allele distribution from the intergroup comparisons of PAI-1 675 4G/5G and VEGF C936T data; however, a significant difference was observed within TGF-β1 G-800A. The linkage disequilibrium analysis revealed that PAI-1 -675 4G and TGF-β1 -800A pair-haplotype was in strong linkage disequilibrium with a significantly increased risk (odds ratio, 3.44; 95% confidence interval, 1.66-7.25) to UCC.
  
  
  CONCLUSIONS
  The polymorphisms in the genes related to angiogenesis -675 4G/5G PAI-1 and G-800A TGF-β1, segregated solely or combined, might contribute to the increased susceptibility to UCC in a Mexican population.
authors.affiliation: Faculty of Medicine, University of Colima, Colima, México.
authors.forename: Christian
authors.initials: C
authors.lastname: Ramos-Flores
authors.forename: Teresa
authors.initials: T
authors.lastname: Romero-Gutiérrez
authors.forename: Iván
authors.initials: I
authors.lastname: Delgado-Enciso
authors.forename: Gabriela Enríquez
authors.initials: GE
authors.lastname: Maldonado
authors.forename: Víctor Montaño
authors.initials: VM
authors.lastname: Plascencia
authors.forename: Oscar F
authors.initials: OF
authors.lastname: Vazquez-Vuelvas
authors.forename: Antonio
authors.initials: A
authors.lastname: Quintero-Ramos
authors.forename: Roberto Chaparro
authors.initials: RC
authors.lastname: Mejía
authors.forename: Francisco
authors.initials: F
authors.lastname: Espinoza-Gomez
authors.forename: Luz M
authors.initials: LM
authors.lastname: Baltazar-Rodriguez
authors.forename: Laura L
authors.initials: LL
authors.lastname: Valdez-Velazquez
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000235:genetics*; D016022:Case-Control Studies; D002584:Cervix Uteri / Q000378:metabolism; D005260:Female; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D015810:Linkage Disequilibrium; D008800:Mexico / Q000453:epidemiology; D009389:Neovascularization, Pathologic / Q000235:genetics*; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D016133:Polymerase Chain Reaction; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D053773:Transforming Growth Factor beta1 / Q000235:genetics*; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000235:genetics*; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D017395:Plasminogen Activator Inhibitor 1; D053773:Transforming Growth Factor beta1; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A